ClinicalTrials.gg
RecruitingNCT06934642Updated Sep 4, 2026

Effect of Tirzepatide on Markers of MASLD in Patients With Obesity

An Early Phase 1 interventional study of Tirzepatide in MASLD and Obesity, sponsored by University of New Mexico. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by University of New Mexico · Early Phase 1, Interventional, and Other

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 78 under way, 14 of them phase 3. Tirzepatide · Obesity.

Planned enrollment
101st of 104
8 · median 69
Started
2025
with 33 others
Phase 1
12 of 104
5 open now
Primary completion
2026-10
later than 7 of 77 live
Registered
52nd of 104
by date

Among the 104 studies testing tirzepatide in Obesity, this one is the 101st largest by planned enrollment, is one of 34 that started in 2025, is one of 12 in phase 1, reaches primary completion later than 7 of the 77 other live ones, and was the 52nd registered.

Obesity

11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

Browse Obesity studies →

Open to participants now

60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

55 more — sign in →

By country, each count listing its studies:

All 60 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,343 Obesity studies recruiting now, 377 (28%) set no upper age limit and 862 (64%) stop at 75 or younger; 168 take children under 18; 488 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing tirzepatide in Obesity, or all of them as a file.
02

Study summary

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease worldwide and predominately affects individuals with overweight and obesity, as well as those with type 2 diabetes and cardiovascular disease. Tirzepatide is a medication used to treat type 2 diabetes and obesity. It has also been shown to help with MASLD. The purpose of this study is to study how tirzepatide affects the liver in patients with MASLD.

Participants will be asked to:

  • Take tirzepatide for 12 months.
  • Come in for clinic visits every 3 months.
  • Have blood drawn at baseline, 6, and 12 months.
  • Complete a liver ultrasound at baseline and at 12 months.
03

Conditions studied

  • MASLD
  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women
  • Age 18-75
  • Diagnosis of MASLD based on the following criteria:

    • Presence of at least 1 out of the 5 following cardiometabolic criteria:
  • >25 kg/m2 OR waist circumference >94 cm (men) or 80cm (women)
  • Fasting serum glucose >100 mg/dL OR 2-hour post-prandial glucose levels >140mg/dL OR AbA1c >5.7% OR type 2 diabetes OR treatment for type 2 diabetes
  • Blood pressure >130/85 mmHg OR specific antihypertensive drug treatment
  • Plasma triglycerides >150mg/dL OR on lipid lowering treatment
  • Plasma HDL-cholesterol \<40mg/dL (men) and \<50mg/dL (women) OR on lipid lowering medication

    • No other identified causes of steatosis
    • Evidence of steatotic liver disease (hepatic steatosis identified by imaging or )
  • English speaking

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breast feeding
  • Premenopausal women not on any form of
  • Reports alcohol intake >50g/day or 350g/week for women and >60g/day or 420g/week for men or an AUDIT score >8
  • Other identifiable causes of steatosis
  • Documented allergic reaction to tirzepatide or any other GLP1 RA
  • Decompensated liver disease
  • Decompensated renal disease requiring hemodialysis
  • Decompensated heart failure
  • Active
  • Prior history of pancreatitis
  • Serum triglyceride levels >500 mg/dL
  • Personal or family history of medullary thyroid cancer or MEN2a or MEN2b
  • Concurrent use of other ant-obesity medications
  • Use of other GLP1 RAs within 3 months of study enrollment
  • Unable to obtain the medication due to cost or insurance coverage restrictions.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Early Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    Intervention Arm

    Individuals in the intervention arm (only arm) will receive tirzepatide for 12 months.

    Drug: Tirzepatide

Interventions

  • The drug is being studied to better understand the biological effects of tirzepatide on MASLD.

    Also known as: Zepbound, Mounjaro

06

What researchers measure

Primary outcomes

  1. Biomarkers associated with MASLD

    Identification of an changes in biomarkers associated with MASLD with tirzepatide use

    Time frame: 12 months

Secondary outcomes

  1. Liver Fat Content

    Change in liver fat content with use of tirzepatide

    Time frame: 12 months

  2. Liver Stiffness

    Change in liver stiffness with use of tirzepatide

    Time frame: 12 months

  3. Body weight

    Change in body weight with use of tirzepatide

    Time frame: 12 months

  4. Metabolic markers

    Changes in lipid profiles, glycemic measures (A1c), inflammatory markers and cytokines, and gut hormones

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • University of New Mexico Health Sciences Center
    Albuquerque, New Mexico 87131, United States
    Recruiting
    • Kristen Gonzales, MD · ContactKrGonzales@salud.unm.edu · 505-272-3840
    • Kristen Gonzales, MD · Principal investigator
    • Eliseo Castillo, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared with other researchers. Data will only be available to study team members.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Oct 2026, 16 months after the start.

Of 105 non-industry phase 1 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 57. This study's planned 16 months is below that.

Counting every sponsor, half of 441 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2025
First posted
Apr 18, 2025
StartActual
Jun 30, 2025
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2026
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06934642
Collaborators
American Cancer Society, Inc., University of New Mexico Cancer Center
Responsible party
Sponsor
First posted
Apr 18, 2025
Start date
Jun 30, 2025
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Sep 4, 2026

Study contacts

Kristen Gonzales, MD
Contact
KrGonzales@salud.unm.edu
15052723840
Eliseo Castillo
principal investigator · UNM Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion